Mainstream

Exagen outlines $65M–$70M 2025 revenue target and positive adjusted EBITDA trajectory while advancing biomarker pipeline

Exagen outlines $65M–$70M 2025 revenue target and positive adjusted EBITDA trajectory while advancing biomarker pipeline

Post ContentxgnRead More

You might also be interested in reading Kinder Morgan in charts: Adjusted EBITDA from natural gas pipelines dips in Q2.

July 29, 2025
In Mainstream